CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 4.48: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.28BCNY639.32M · vs all stocks (USD)
Revenue (TTM)
408.33MCNY60.98M · vs all stocks (USD)
Profit Margin
-33.40%Beta
0.2420xvs all stocks
52-Week Change
7.51%vs all stocks
Market Capitalization
4.28BCNY639.32M · vs all stocks (USD)
Enterprise Value
4.31BCNY643.19M · vs all stocks (USD)
Forward P/E
14.29xPrice to Sales (TTM)
10.47xPrice to Book (MRQ)
6.58xEnterprise to Revenue
10.55xEnterprise to EBITDA
-146.28xGross Margin
47.62%Profit Margin
-33.40%Operating Margin
13.82%Return on Assets (TTM)
-2.93%Return on Equity (TTM)
-19.83%Revenue (TTM)
408.33MCNY60.98M · vs all stocks (USD)
Revenue per Share (TTM)
0.5750CNYUpdated Sep 22, 2026Quarterly Revenue Growth
40.70%Gross Profit (TTM)
213.06MCNY31.82M · vs all stocks (USD)
EBITDA (TTM)
-29.45MCNY-4.40M · vs all stocks (USD)
Net Income (TTM)
-136.39MCNY-20.37M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
241.02%Operating Cash Flow (TTM)
-108.11MCNY-16.14M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-128.30MCNY-19.16M · vs all stocks (USD)
5-Year Average Dividend Yield
3.01%vs all stocks
Payout Ratio
0.00%Revenue
322.48MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
181.52MCNYFY2025 · Dec 31, 2025Gross Profit
140.97MCNYFY2025 · Dec 31, 2025Operating Income
-93.26MCNY-13.93M · vs all stocks (USD)
Pre-tax Income
-193.51MCNYFY2025 · Dec 31, 2025Income Tax Expense
-275.08KCNYFY2025 · Dec 31, 2025Net Income
-193.24MCNYFY2025 · Dec 31, 2025EBIT
-172.32MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-101.82MCNYFY2025 · Dec 31, 2025Research & Development
12.70MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
163.16MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.70MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
237.87KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
21.20MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.2700CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.2700CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
715.70MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
715.70MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-193.24MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-222.32MCNYFY2025 · Dec 31, 2025Free Cash Flow
-226.65MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
153.21MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-193.24MCNYFY2025 · Dec 31, 2025Other Non-cash Items
24.70MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
6.32MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-60.11MCNYFY2025 · Dec 31, 2025Capital Expenditures
4.33MCNYFY2025 · Dec 31, 2025Sale of Investments
10.80MCNYFY2025 · Dec 31, 2025Other Investing Activity
17.33MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
32.46MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
15.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-6.59MCNYFY2025 · Dec 31, 2025Other Financing Charges
-2.07MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
6.34MCNYFY2025 · Dec 31, 2025Shares Outstanding
712.33MSharesUpdated Sep 22, 2026Float Shares
266.56MSharesUpdated Sep 22, 2026% Held by Insiders
61.87%vs all stocks
% Held by Institutions
1.61%vs all stocks
Total Cash (MRQ)
165.09MCNY24.65M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.2350CNYUpdated Sep 22, 2026Total Debt (MRQ)
321.32MCNY47.98M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5010xCurrent Ratio (MRQ)
1.22xBook Value per Share (MRQ)
0.9120CNYUpdated Sep 22, 2026Total Assets
1.11BCNY165.28M · vs all stocks (USD)
Total Current Assets
525.38MCNYFY2025 · Dec 31, 2025Total Liabilities
486.50MCNYFY2025 · Dec 31, 2025Total Non-current Assets
581.40MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
7.92MCNYFY2025 · Dec 31, 2025Total Current Liabilities
478.58MCNYFY2025 · Dec 31, 2025Cash
155.50MCNYFY2025 · Dec 31, 2025Cash Equivalents
7.82KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
155.51MCNYFY2025 · Dec 31, 2025Other Short-term Investments
13.32MCNYFY2025 · Dec 31, 2025Accounts Receivable
256.11MCNYFY2025 · Dec 31, 2025Inventory
84.03MCNYFY2025 · Dec 31, 2025Accounts Payable
129.12MCNYFY2025 · Dec 31, 2025Short-term Debt
289.55MCNYFY2025 · Dec 31, 2025Other Current Liabilities
3.01MCNYFY2025 · Dec 31, 2025Long-term Debt
2.13MCNYFY2025 · Dec 31, 2025Common Stock (Book)
721.25MCNYFY2025 · Dec 31, 2025Retained Earnings
-499.92MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
620.28MCNY92.63M · vs all stocks (USD)
Treasury Stock
110.02MCNYFY2025 · Dec 31, 202552-Week Low
4.01CNYUpdated Sep 22, 202652-Week High
8.40CNYUpdated Sep 22, 202652-Week Change
7.51%vs all stocks
Beta
0.2420xvs all stocks
50-Day MA
5.73CNYUpdated Sep 22, 2026200-Day MA
4.96CNYUpdated Sep 22, 2026Avg 10-Day Volume
30.29MSharesUpdated Sep 22, 2026Avg 30-Day Volume
25.51MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-0.1900CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.48Profit Margin: -0.33
Financial Health
Altman Z-Score 4.48: safe zoneNotable
Altman Z-Score: 4.48
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
ProKidney Corp
Tier 1ProductionApproval-Gated PipelineRule
Contec Medical Systems Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hangzhou Minsheng Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hvsen Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xiangxue Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vishee Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jianmin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sailun Biotech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Lisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lanzhou Foci Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule